Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 8, 2003Journal of Medicinal ChemistryOpen Access

Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChristopher S. BurgeyMerck & Co., Inc., Rahway, NJ, USA (United States)KRKyle A. RobinsonPurdue University West LafayetteTLTerry A. LyleUnited States Military Academy

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Burgey et al. (2003) studied this question.

synapsesocial.com/papers/6a84312cdc9bcdcbf8c6bbb1https://doi.org/10.1021/jm020311f
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kilogram Scale Synthesis of the Pyrazinone Acetic Acid Core of an Orally Efficacious Thrombin Inhibitor2000 · 28 citations
  2. 2Factors Involved in the N-Oxidation of Isomeric Aromatic Diazines by Microsomal Preparations1995 · 3 citations
  3. 3Design of Novel, Potent, Noncovalent Inhibitors of Thrombin with Nonbasic P-1 Substructures: Rapid Structure−Activity Studies by Solid-Phase Synthesis1998 · 86 citations
  4. 4A Simple and Efficient Method for the Preparation of Pyridine N -Oxides1998 · 149 citations
  5. 5Small-molecule direct thrombin inhibitors: 1997 - 20002001 · 45 citations